Free tool
FAERS Monitor: Monodox
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050641 or its brand name (Monodox, Doxycycline). Reports on generic versions are filed under their own applications.
Reports
53,422
Serious
41,375
77% of reports
Hospitalization
18,296
Death reported
4,956
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,220
- off label use3,727
- nausea3,691
- fatigue3,327
- dyspnoea3,154
- rash3,090
- diarrhoea3,040
- headache2,878
- pain2,867
- vomiting2,840
- malaise2,385
- condition aggravated2,196
- chronic kidney disease2,158
- pyrexia2,139
- arthralgia2,097
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 221 |
| 2005 | 316 |
| 2006 | 318 |
| 2007 | 351 |
| 2008 | 418 |
| 2009 | 681 |
| 2010 | 930 |
| 2011 | 1,144 |
| 2012 | 1,301 |
| 2013 | 1,415 |
| 2014 | 1,657 |
| 2015 | 2,028 |
| 2016 | 2,664 |
| 2017 | 2,772 |
| 2018 | 3,495 |
| 2019 | 4,345 |
| 2020 | 4,138 |
| 2021 | 3,627 |
| 2022 | 3,919 |
| 2023 | 4,687 |
| 2024 | 4,930 |
| 2025 | 4,749 |
| 2026 | 3,316 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,000,737 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 2,158 | 11.5 | 11.0 | 20,121 |
| condition aggravatedSignal | 2,196 | 2.9 | 2.7 | 2,668 |
| rashSignal | 3,090 | 2.8 | 2.7 | 3,634 |
| pyrexiaSignal | 2,139 | 2.4 | 2.3 | 1,840 |
| vomitingSignal | 2,840 | 2.4 | 2.3 | 2,325 |
| dyspnoeaSignal | 3,154 | 2.2 | 2.1 | 2,109 |
| malaiseSignal | 2,385 | 2.1 | 2.1 | 1,484 |
| arthralgia | 2,097 | 2.0 | 1.9 | 1,048 |
| diarrhoea | 3,040 | 1.9 | 1.8 | 1,236 |
| pain | 2,867 | 1.8 | 1.8 | 1,129 |
| nausea | 3,691 | 1.8 | 1.8 | 1,463 |
| headache | 2,878 | 1.8 | 1.7 | 1,072 |
| fatigue | 3,327 | 1.7 | 1.6 | 958 |
| off label use | 3,727 | 1.7 | 1.6 | 1,062 |
| drug ineffective | 4,220 | 1.3 | 1.2 | 243 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.